GlassScriptPhysician profile
Michael Todd Mckelvey
NPI 1063477008
$26,697.30
in general payments reported to CMS, 2019-2025
52 companies · $4,949 in 2025
The $4,949 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,937 · 2020: $3,068 · 2021: $3,577 · 2022: $3,231 · 2023: $4,148 · 2024: $4,787 · 2025: $4,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,330.18 |
| Education | $553.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,544.25 | 2019-2025 | |
| Janssen Biotech, INC. | $2,912.75 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,946.04 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,765.49 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Genzyme Corporation | $1,513.70 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,455.24 | 2019-2025 | Siliq, Arazlo, Cabtreo |
| Ucb, INC. | $1,180.37 | 2019-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $1,167.27 | 2019-2025 | |
| Leo Pharma INC. | $1,070.20 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $1,045.30 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $997.96 | 2019-2025 | |
| Lilly USA, LLC | $803.15 | 2019-2025 | Taltz, Ebglyss |
| Incyte Corporation | $738.96 | 2021-2025 | Opzelura |
| Journey Medical Corporation | $681.87 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $669.10 | 2019-2025 | Dupixent, Libtayo |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $547.74 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $507.31 | 2021-2024 | Sotyktu |
| Biofrontera INC. | $504.90 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $460.03 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $443.17 | 2019-2025 | Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $423.54 | 2022-2024 | Vtama |
| Almirall LLC | $277.11 | 2019-2025 | Seysara, Klisyri |
| Epi Health, LLC | $245.77 | 2019-2022 | |
| Allergan, INC. | $236.17 | 2021-2022 | |
| Organon LLC | $230.28 | 2025 | Vtama, Nexplanon |
| Celgene Corporation | $182.09 | 2019 | |
| Dermira, INC. | $141.58 | 2019-2021 | |
| Medimetriks Pharmaceuticals, INC. | $129.80 | 2020-2024 | Neo-Synalar, Neuac |
| Organogenesis INC. | $80.67 | 2020-2025 | Simplimax |
| Verrica Pharmaceuticals INC. | $76.46 | 2023-2025 | Ycanth |
| Aclaris Therapeutics, INC. | $74.56 | 2019 | |
| Sebela Pharmaceuticals INC. | $74.13 | 2021-2022 | |
| Encore Dermatology INC. | $67.16 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $64.52 | 2024 | Nuzyra |
| Integra Lifesciences Corporation | $62.34 | 2019 | |
| Merz North America, INC. | $59.60 | 2019-2023 | Xeomin |
| Janssen Scientific Affairs, LLC | $52.86 | 2020-2025 | Tremfya |
| Convatec INC. | $26.34 | 2023 | |
| Pierre Fabre Pharmaceuticals, INC. | $24.95 | 2025 | Hemangeol |
| Botanix Sb INC | $22.06 | 2025 | Sofdra |
| Krystal Biotech INC | $21.94 | 2023 | Vyjuvek |
| Kerecis Limited | $20.51 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Sandoz INC. | $19.36 | 2019 | |
| Promius Pharma LLC | $18.88 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.66 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $15.88 | 2022 | |
| Ani Pharmaceuticals, INC. | $15.43 | 2023 | Veregen |
| Strata Skin Sciences, INC. | $14.69 | 2025 | Xtrac |
| Medline Industries LP | $13.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Stemline Therapeutics INC. | $12.56 | 2022 | |
| Sanofi-Aventis U.S. LLC | $7.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mckelvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.